In the HARMONY Alliance Study of European randomized clinical trials, researchers sought to determine if MRD could serve as an intermediate endpoint in intensively treated AML.

This systematic review focusing on the targeted therapy era found solid associations between measurable residual disease (MRD) and clinical outcomes in patients with chronic lymphocytic leukemia.

A conditioning regimen free from total body irradiation (TBI) appeared to be just as effective as standard of care (SoC) in a ...

Sensitive tests designed to detect very small numbers of remaining leukemia cells after treatment, known as measurable ...

NPM1 minimal residual disease (MRD) positivity before allogeneic hematopoietic cell transplantation is linked to higher relapse rates and lower overall survival in patients with acute myeloid leukemia ...

MRD negativity post-chemotherapy strongly predicts improved overall survival in AML, with a significant reduction in mortality risk. The study suggests MRD could serve as an earlier surrogate endpoint ...

This transcript has been edited for clarity. Gail J. Roboz, MD: Hi, everyone. My name is Dr Gail Roboz. I'm a professor of medicine and director of the leukemia program at Weill Cornell Medicine and ...

A chemotherapy-free regimen significantly improved outcomes compared with standard therapy for newly diagnosed Ph+ acute ...

Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and ...

Chronic lymphocytic leukemia (CLL) remains an incurable disease, except in rare cases treated with allogeneic stem-cell transplantation or favorable-risk CLL treated with chemoimmunotherapy. Treatment ...